

# REVENIO

---

## Revenio Group Corporation: The Chairman of the Board of Revenio will resign at the spring 2022 Annual General Meeting

**Revenio Group Corporation, Stock Exchange Release, November 16, 2021 at 17:00**

### **The Chairman of the Board of Revenio will resign at the spring 2022 Annual General Meeting**

Pekka Rönkä, a long-term member and Chairman of the Board of Revenio Group Corporation, has announced that he will retire and is no longer available for a Board position at Revenio's 2022 Annual General Meeting.

The Nomination and Remuneration Committee of Revenio's Board of Directors has begun identifying potential Board member candidates for the spring 2022 Annual General Meeting following the normal process. The Annual General Meeting will elect the future Board of Directors, and the elected Board will nominate the new Chairman among its members.

#### **Pekka Rönkä, Chairman of the Board, comments:**

"I am extremely proud and excited about Revenio's growth path and our shared accomplishments. During my term of office, Revenio has become a truly international, eye-focused corporation and a respected representative of the industry, in line with its strategy. In addition, the company's ownership base has expanded significantly, market value has increased, and share liquidity is excellent. I feel that now is the right time, both for me personally and for Revenio, to notify that I will not be available for a board position at the next Annual General Meeting."

Revenio Group Corporation  
Board of Directors

#### **For further information, please contact:**

Jouni Toijala, President & CEO, tel. +358 50 484 0085  
jouni.toijala@revenio.fi  
Robin Pulkkinen, CFO, tel. +358 50 505 9932  
robin.pulkkinen@revenio.fi  
www.revenio.fi

#### **DISTRIBUTION:**

Nasdaq Helsinki Oy  
Financial Supervisory Authority (FIN-FSA)  
Principal media  
<https://www.reveniogroup.fi/en/>

# REVENIO

---

## Revenio Group in brief

Revenio is a leading company in ophthalmological devices and software solutions. Revenio Group's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), retinal imaging devices, and perimeters under the iCare brand. In addition, the Group's eye care software platform Oculo brings together clinical communication, telehealth, remote patient monitoring, and data analytics capabilities.

In 2020, the Group's net sales totaled EUR 61.1 million, and its operating profit amounted to EUR 17.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

## Attachments

---

[Revenio Group Corporation: The Chairman of the Board of Revenio will resign at the spring 2022 Annual General Meeting](#)